Brief: Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme

Humanigen

09/04/2021 12:04

April 9 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF
IFABOTUZUMAB IN GLIOBLASTOMA MULTIFORME
    * HUMANIGEN INC - PHASE 1 DOSE ESCALATION AND BIOIMAGING
STUDY
SHOWS THAT IFABOTUZUMAB DEMONSTRATES HIGHLY SPECIFIC TUMOR
TARGETING IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Source text for Eikon:  ID:nBw6mV0npa 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))